Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2018-07-23

FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approved a supplemental application for Lamictal (lamotrigine) from GlaxoSmithKline, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LAMICTAL (LAMOTRIGINE)

Snippet

SUPPL AP for LAMICTAL (LAMOTRIGINE)